Dana-Farber, Gustave Roussy Host Oncology Drug Talks

The Fifth Transatlantic Exchange in Oncology will feature leading cancer researchers and clinicians from the US and Europe.

Published on Feb. 14, 2026

Got story updates? Submit your updates here. ›

Dana-Farber Cancer Institute will host the Fifth Transatlantic Exchange in Oncology on Friday, March 27, 2026, bringing together leading cancer researchers and clinicians from the United States and Europe to explore transatlantic innovations in cancer drug research. The full-day meeting will highlight emerging research and therapeutic approaches aimed at accelerating progress in cancer treatment worldwide.

Why it matters

The Transatlantic Exchange series has previously examined cutting-edge topics in oncology, helping to facilitate global scientific collaboration and advance cancer research and care. This latest event continues that mission, connecting the best minds across continents to share ideas and drive innovation in the fight against cancer.

The details

The meeting will feature scientific discussions on advances in epigenetic therapies, microbiome-driven immunity, and cellular pathway reprogramming, spanning translational research through clinical application. Attendees will discover breakthrough technologies and transformative approaches that promise to redefine cancer care worldwide.

  • The Fifth Transatlantic Exchange in Oncology will be held on Friday, March 27, 2026.

The players

Dana-Farber Cancer Institute

A comprehensive cancer center in Boston, Massachusetts, that conducts research and provides clinical care.

Gustave Roussy

A comprehensive cancer center in France that collaborates with Dana-Farber on the Transatlantic Exchange in Oncology.

Toni K. Choueiri, MD

Medical director of International Strategic Initiatives and director of the Lank Center for Genitourinary Oncology at Dana-Farber and Harvard Medical School, who will co-chair the meeting.

Alexandra Leary, MD, PhD

Lead for International Academic Partnerships and deputy director of the Department of Medical Oncology at Gustave Roussy.

Caroline Phillips

Vice president of Medscape Medical Affairs, which is supporting the Transatlantic Exchange initiative.

Patrick Therasse

Managing director of L'Institut Servier, which is supporting the Transatlantic Exchange initiative.

Got photos? Submit your photos here. ›

What they’re saying

“Our meetings connect the best minds in oncology across continents to share and discuss emerging trends and the latest innovations, from translational research to clinical care. The goal is to help facilitate our shared aim - to cure cancer.”

— Toni K. Choueiri, MD, Medical director of International Strategic Initiatives and director of the Lank Center for Genitourinary Oncology at Dana-Farber and Harvard Medical School (Mirage News)

“Cancer knows no borders, and neither should innovation. By bringing together bold ideas, diverse expertise, and a common purpose, this transatlantic partnership is advancing science and building hope for patients around the world.”

— Alexandra Leary, MD, PhD, Lead for International Academic Partnerships and deputy director of the Department of Medical Oncology at Gustave Roussy (Mirage News)

“The Transatlantic Exchange is a project we are always honored to be part of. Everyone involved is deeply committed to delivering educational programs that have a meaningful impact for participants and for the broader oncology community.”

— Caroline Phillips, Vice president of Medscape Medical Affairs (Mirage News)

“By bringing together leading experts from both sides of the Atlantic, we foster innovation and accelerate progress toward better outcomes for patients everywhere.”

— Patrick Therasse, Managing director of L'Institut Servier (Mirage News)

What’s next

The Fifth Transatlantic Exchange in Oncology is free to attend and open to healthcare professionals with an interest in oncology. In-person and virtual registration is now open.

The takeaway

This transatlantic collaboration between leading cancer centers and organizations aims to drive innovation in oncology research and care, leveraging global expertise and diverse perspectives to accelerate progress in the fight against cancer.